Cara Therapeutics Inc. (NASDAQ:CARA) was down 1.1% on Friday . The stock traded as low as $5.27 and last traded at $5.32, with a volume of 215,085 shares. The stock had previously closed at $5.38.

Several equities research analysts recently weighed in on CARA shares. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Cara Therapeutics in a research report on Friday, August 5th. Needham & Company LLC reaffirmed a “buy” rating on shares of Cara Therapeutics in a research report on Friday, May 6th. Stifel Nicolaus cut their price objective on shares of Cara Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, August 5th. Zacks Investment Research cut shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 11th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $30.00 price objective on shares of Cara Therapeutics in a research report on Friday, May 6th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $21.06.

The stock’s market capitalization is $145.14 million. The firm has a 50 day moving average of $5.76 and a 200 day moving average of $5.88.

Cara Therapeutics (NASDAQ:CARA) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.06. The firm earned $0.08 million during the quarter, compared to analysts’ expectations of $0.13 million. The company’s revenue was down 91.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.25) earnings per share. On average, equities research analysts forecast that Cara Therapeutics Inc. will post ($1.81) earnings per share for the current year.

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.